A5053795300- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Pediatric Urology and Nephrology Studies
- Urologic and reproductive health conditions
- Pelvic floor disorders treatments
- Urinary Bladder and Prostate Research
- Ureteral procedures and complications
- Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Kidney Stones and Urolithiasis Treatments
- Innovations in Medical Education
- Reproductive Health and Technologies
- Cancer Immunotherapy and Biomarkers
- Surgical Simulation and Training
- COVID-19 and healthcare impacts
- Bone health and treatments
- Anorectal Disease Treatments and Outcomes
- Pelvic and Acetabular Injuries
- Sexual function and dysfunction studies
- Infectious Disease Case Reports and Treatments
- Epigenetics and DNA Methylation
Hospital Universitario Puerta del Mar
2014-2023
Karamanoğlu Mehmetbey University
2022
Chelsea and Westminster Hospital
2022
Lebanese American University
2022
University of Iowa Hospitals and Clinics
2022
American University of Beirut Medical Center
2022
Asociación Española de Urología
2013
Universidad de Cádiz
1992
Androgen deprivation therapy may promote the development of metabolic syndrome in patients with prostate cancer. We assessed prevalence full and its components during first year androgen therapy.This observational, multicenter, prospective study included 539 cancer scheduled to receive 3-month depot luteinizing hormone-releasing hormone analogs for more than 12 months. Waist circumference, body mass index, lipid profile, blood pressure fasting glucose were evaluated at baseline after 6 The...
Changes in DNA methylation of tumor suppressor genes early carcinogenesis represent potential indicators cancer detection and disease evolution. We examined the diagnostic, stratification prognostic biomarker roles urine a novel panel bladder cancer.We evaluated 18 2 prospective, independent sets samples (training set 120 preparations validation 128) from patients with (170) controls (78) using specific multiplex ligation-dependent probe amplification. Diagnostic performance was ROC curves....
Aim To evaluate effectiveness and safety of the adjustable transobturator male system (ATOMS) for stress urinary incontinence (SUI). Material Methods A retrospective multicenter study was conducted in nine Iberian institutions using a board‐approved database 215 patients intervened between 2012 2017, with no case excluded. Continence status, patient satisfaction, number, grade complications (Clavien‐Dindo) factors affecting dry rate at adjustment were evaluated. Multivariate analysis defined...
Owing to the limited validity of clinical data on treatment prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression skeletal-related events (SREs) in these patients. The aim this study was evaluate predictive capacity turnover mortality risk, SREs patients with PCa metastases undergoing zoledronic acid (ZA). This an observational, prospective multicenter which ninety-eight were included. Patients treated ZA (4 mg every...
DNA methylation of tumor suppressor genes (TSGs) represents a frequent and early epigenetic event with potential applications for cancer detection disease evolution. Our aim was to examine the stratification prognostic biomarker role novel panel TSGs in bladder cancer. The status 18 evaluated cells (n=14) paraffin-embedded primary tumors (n=61), using methylation-specific multiplex ligation-dependent probe amplification assay (MS-MLPA). Recurrence, progression, disease-specific survival were...
Renal angiomyolipomas (AML) are usual manifestations of tuberous sclerosis complex (TSC) that may cause aneurism-related haemorrhages and renal impairment. Everolimus has emerged as an alternative to surgery/embolization. We provide further insight into everolimus safety efficacy for TSC-related AML. This was a Spanish expanded access trial including patients aged ≥18 years with They received 10 mg once daily until AML progression, unacceptable toxicity, death/withdrawal, commercialisation...
Myopodin is a cytoskeleton protein that shuttles to the nucleus depending on cellular differentiation and stress. It has shown tumor suppressor functions. methylation status was useful for staging bladder colon tumors predicting clinical outcome. To our knowledge, myopodin not been tested in kidney cancer date. The purpose of this study evaluate whether could be clinically renal (1) as prognostic biomarker 2) predictive factor response antiangiogenic therapy patients with metastatic disease....
Aim: Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes Spanish participants ARAMIS. Patients & methods: with high-risk nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide 600 mg twice daily or placebo, plus androgen-deprivation therapy. The primary end point was MFS. Descriptive statistics are reported for this post hoc analysis. Results: In participants, (n = 75) MFS 42):...